Neurogene initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Neurogene with a Buy rating and $45 price target. Neurogene is a clinical-stage biotech company developing gene therapies to treat rare diseases, the analyst tells investors in a research note. The firm believes NGN-401 will serve as proof-of-concept for the EXACT platform and its many applications across diseases that require defined protein levels for precise therapeutic effects.